Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT: Relacorilant + Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Adenocarcinoma
NCT07259317Phase 2Recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Jan 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of relacorilant in pancreatic adenocarcinoma (PDAC), sponsored by Corcept Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
relacorilant
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07259317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259317.